The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
79 Own result · 10 Own method · 8 Own interpretation · 4 Sources not found · 2 Partly supported · 2 No basis given · 1 Supported · 1 Supported so far · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
plainn = 112- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
plainn = 52- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
plainn = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
plaincorrelationaln = 127- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
plainn = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
plainn = 54- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
plaincorrelationaln = 127- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
plaincorrelationaln = 54- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
plainn = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
plainn = 88- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
plainn = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
plaincorrelationaln = 28- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
plainn = 114- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
plainn = 44- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
plaincorrelationaln = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
plainn = 33- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
plainn = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
plainn = 140- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
plainn = 128- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Cited by
Sorted by citations
Items 501–600 of 2,535
Chung, D. J., Shah, N. D., Wu, J., Logan, B. R., Bisharat, L., Callander, N. S., Cheloni, G., Anderson, K. C., Chodon, T., Dhakal, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0235 · Cited by 33
“Chimeric antigen receptor (CAR) T-cell therapy has demonstrated dramatic responses in patients with relapsed/refractory disease, illustrating the potential uniqueef fi cacyofimmuneeffectorcellsintargeting multiplemyeloma that is resistant to standard biologic agents (8, 9).”
BackgroundSelf-citationde Assis, L. H., Fassi, D. E., & Hutchings, M. (2023) · Hematology · doi:10.1182/hematology.2023000508 · Cited by 33
Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
McCurdy, A. B. R., Seow, H. Y., Pond, G. R., Gayowsky, A., Chakraborty, R., Visram, A., Kaedbey, R., D’Souza, A., Mohyuddin, G. R., Wildes, T. M., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.282905 · Cited by 30
Cytokine signaling in chimeric antigen receptor T-cell therapy
Kagoya, Y. (2023) · International Immunology · doi:10.1093/intimm/dxad033 · Cited by 31
Talquetamab in multiple myeloma
Liu, L., & Krishnan, A. Y. (2023) · Haematologica · doi:10.3324/haematol.2023.283931 · Cited by 29
Peres, L. C., Oswald, L. B., Dillard, C. M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010894 · Cited by 29
“6 In the recent KarMMa-3 trial, 7 only 7% of the patient population treated with ide-cel self-reported a Black race, and Hispanic ethnicity was not reported.”
BackgroundSelf-citationOluwole, O. O., Dholaria, B., Knight, T. E., Jain, T., Locke, F. L., Ramsdell, L. A., Nikiforow, S., Hashmi, H., Mooney, K., Bhaskar, S., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.11.008 · Cited by 29
Self-citationDima, D., Rashid, A., Davis, J. A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19302 · Cited by 29
Ma, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 35
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38
Hasegawa, K., Ikeda, S., Yaga, M., Watanabe, K., Urakawa, R., Iehara, A., Iwai, M., Hashiguchi, S., Morimoto, S., Fujiki, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7706 · Cited by 29
How I treat triple‐class refractory multiple myeloma
Costa, L. J., Hungria, V., Mohty, M., & Mateos, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18185 · Cited by 29
Camilli, M., Maggio, L., Tinti, L., Lamendola, P., Lanza, G. A., Crea, F., & Lombardo, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1090103 · Cited by 29
“As well, in ZUMA-1 trial, a case of cardiac arrest occurred in a patient with grade 5 CRS (12, 15, 22, 44).”
BackgroundInfluentialAnti-BCMA novel therapies for multiple myeloma
Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., Bocchia, M., & Gozzetti, A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.138 · Cited by 32
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 32
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Xiang, M., Li, H., Zhan, Y., Ma, D., Gao, Q., & Fang, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01987-z · Cited by 29
“…maturation antigen (BCMA)-targeted CAR-T cell therapies reported an overall response rate (ORR) of over 70%, complete response rates ranging from 33 to 83%, and varied median progression-free survival in patients with RRMM, indicating prolonged remissions after CAR-T cell therapies [11, 37–39].”
BackgroundSutherland, N. M., Zhou, B., Zhang, L., Ong, M., Hong, J., Pak, A., Liu, K. J., Frigault, M. J., Maus, M. V., Hill, J. A., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.10.021 · Cited by 34
Wang, Z., & Kelley, S. O. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01315-2 · Cited by 33
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Sidana, S., Ahmed, N., Akhtar, O. S., Brazauskas, R., Oloyede, T., Bye, M., Hansen, D. K., Ferreri, C. J., Freeman, C. L. L., Afrough, A., et al. (2025) · Blood · doi:10.1182/blood.2024026216 · Cited by 32
Self-citationTedder, B., & Bhutani, M. (2025) · Cells · doi:10.3390/cells14141077 · Cited by 33
“Clinically approved CAR T-cell therapies, such as Idecabtagene Vicleucel (Ide-cel) and Ciltacabtagene Autoleucel (Cilta-cel), as well as BsAbs like Teclistamab and Elranatamab, have significantly improved outcomes in heavily pretreated patients [4–10].”
InfluentialAdoptive Cellular Therapy for Solid Tumors
Bear, A. S., Fraietta, J. A., Narayan, V., O’Hara, M. H., & Haas, N. B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321115 · Cited by 31
Advances in mRNA-based drug discovery in cancer immunotherapy
Trani, C. A. D., Fernández-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1978972 · Cited by 28
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy
Paul, B. A., Rodriguez, C., & Usmani, S. Z. (2022) · Drugs · doi:10.1007/s40265-022-01697-0 · Cited by 28
“Interestingly, 93% of patients who progressed still had detectable levels of cellular BCMA on their MM cells, suggesting that antigen loss is not a dominant mechanism for resistance [135, 136].”
BackgroundHow I approach smoldering multiple myeloma
Vaxman, I., & Gertz, M. A. (2022) · Blood · doi:10.1182/blood.2021011670 · Cited by 28
Xiao, X., Wang, Y., Zou, Z., Yang, Y., Wang, X., Xin, X., Tu, S., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954235 · Cited by 28
“Ide-cel KarMMa (15) Global 128 73% 33% Median PFS 8.”
BackgroundPrognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
Bansal, R., Baksh, M., Larsen, J. T., Hathcock, M. A., Dingli, D., Stewart, A. K., Kapoor, P., Kourelis, T., Hayman, S. R., Warsame, R. M., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00820-y · Cited by 27
Self-citationLi, R., & Cao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194020 · Cited by 28
“Ide-cel BCMA 4-1BB, CD3-z Celgene FDA R/R MM NCT03361748 Phase II 140/128 CR 33%, ORR 73% (50)”
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
O’Neal, J., Cooper, M. L., Ritchey, J., Gladney, S., Niswonger, J., González, L. S., Street, E., Haas, G. J., Carter, A. J., Amayta, P. N., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010032 · Cited by 30
Katiyar, V., Chesney, J. A., & Kloecker, G. H. (2023) · Cancers · doi:10.3390/cancers15143733 · Cited by 32
“While CAR T-cells have demonstrated significant efficacy and durable responses in advanced refractory hematologic malignancies including Diffuse large B cell lymphoma [13,14], other aggressive B cell lymphomas [15,16], acute lymphocytic leukemia [17], and multiple myeloma [18,19], TILs has been successfully used in me…”
BackgroundCurrent use of bispecific antibodies to treat multiple myeloma
Lee, H., Neri, P. E., & Bahlis, N. J. (2023) · Hematology · doi:10.1182/hematology.2023000433 · Cited by 29
Teoh, J. J., & Brown, L. F. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.013 · Cited by 29
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
Fräßle, S. P., Tschulik, C., Effenberger, M. J. P., Cletiu, V., Gerget, M., Schober, K., Busch, D. H., Germeroth, L., Stemberger, C., & Poltorak, M. P. (2023) · Communications Biology · doi:10.1038/s42003-023-04978-w · Cited by 30
“CAR T cells are very potent in the lysis of cells expressing target antigen (e.g., CD7, CD19 or BCMA), but they do not distinguish between healthy and abnormal cells 13 – 15 .”
Mohan, M., Szabó, A., Patwari, A., Esselmann, J., Patel, T., Bachu, R., Rein, L., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02233-2 · Cited by 31
Self-citationOlaoba, O. T., Yang, M. J., Adelusi, T. I., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16081470 · Cited by 28
Furqan, F., Bhatlapenumarthi, V., Dhakal, B., Fenske, T. S., Farrukh, F., Longo, W., Akhtar, O. S., D’Souza, A., Pasquini, M. C., Murthy, G. S. G., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013239 · Cited by 28
Self-citationStrategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling, M. C., Cole, A. C., Brammer, B., Diatikar, K. G., Schmitt, N. C., & Paulos, C. M. (2024) · Cancers · doi:10.3390/cancers16162858 · Cited by 31
“Abecma and Carvykti are additional CAR T cell products approved for the treatment of multiple myeloma, targeting the B cell maturation antigen (BCMA) expressed on malignant plasma cells in this cancer [10].”
BackgroundImmunosenescence promotes cancer development: from mechanisms to treatment strategies
Wang, L., & Tang, D. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02082-6 · Cited by 32
“In contrast, for patients over the median age of 70, the CR rate drops significantly, ranging from 33 to 73% [130, 131].”
Nanobodies and their derivatives: pioneering the future of cancer immunotherapy
Li, H., Zhou, Q., Cao, N., Hu, C., Wang, J., He, Y. T., Jiang, S., Li, Q., Chen, M., Li, G., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02270-4 · Cited by 32
Andreou, T., Neophytou, C., Kalli, M., Mpekris, F., & Stylianopoulos, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638186 · Cited by 27
Martin, T. G., Usmani, S. Z., Schecter, J. M., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2139052 · Cited by 27
“Similarly, the KarMMa trial protocol was approved by local or independent IRBs or ethics committees at participating sites and all patients provided written informed consent.(9) The current analyses were conducted in accordance with a protocol and statistical analysis plan developed prior to the start of data analysis.”
MethodA novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
Hirayama, A. V. V., Chou, C. K., Miyazaki, T., Steinmetz, R. N., Di, H. A., Fräßle, S. P., Gauthier, J., Fiorenza, S., Hawkins, R. M., Overwijk, W. W., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008697 · Cited by 25
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
“Idecabtagene vicleucel (idecel) is a CAR T-cell therapy that has been shown to induce responses in the majority of MMRR patients who had received at least three prior lines of treatment, achieving MRD-negative status in 26% of treated patients [47].”
BackgroundButt, O. H., Zhou, A. Y., Ances, B. M., DiPersio, J. F., & Ghobadi, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1110647 · Cited by 28
Zhang, Q., Zu, C., Jing, R., Feng, Y., Zhang, Y., Zhang, M., Lv, Y., Cui, J., Zhou, L., Meng, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125357 · Cited by 31
Lee, D. H., Kumar, A., Mohammed, T. J., Peres, L. C., Alsina, M., Bachmeier, C. A., Blue, B. J., Brayer, J. B., Chandrasekhar, S. A., Grajales-Cruz, A. F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009766 · Cited by 28
“• Worse baseline functional status and higher-grade CRS and neurotoxicity are associated with cardiac events after ide-cel CAR-T.”
InfluentialEnabling CAR T ‐cell therapies for HIV ‐positive lymphoma patients – A call for action
Hattenhauer, T., Mispelbaum, R., Hentrich, M., Boesecke, C., & Monin, M. B. (2023) · HIV Medicine · doi:10.1111/hiv.13514 · Cited by 29
Leukapheresis for CAR-T cell production and therapy
Pessach, I., & Nagler, A. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103828 · Cited by 32
ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
Čufer, T., & Kosty, M. P. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101631 · Cited by 28
Wang, D., Fu, H., Que, Y., Ruan, H., Xu, M., Long, X., Yu, Q., Li, C., Li, Z., Cai, S., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04655-w · Cited by 25
“In comparison, previous CAR-T studies have shown that responses of EMM patients were unsatisfactory, with CR rates lower than 60% and a median progression-free survival of no more than 9 months [5, 11, 12].”
ResultZhang, Q., Zhu, X., & Xiao, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05640-z · Cited by 26
“T cell therapy is a rapidly advancing tumor immunotherapy approach that has been widely used and shown to be effective in the treatment of hematologic malignancies, including acute lymphoblastic leukemia [1, 2], non-Hodgkin’s lymphoma [3–5], and multiple myeloma [6, 7].”
BackgroundTalquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions
Labanca, C., Martino, E. A., Vigna, E., Bruzzese, A., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14353 · Cited by 33
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases
Jaeckel, E., Friedman, S. L., Hudecek, M., & Protzer, U. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.007 · Cited by 30
Neurological complications of CAR T cell therapy for cancers
Karschnia, P., & Dietrich, J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01112-8 · Cited by 28
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options
Calvez, B. L., Moreau, P., & Touzeau, C. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1955103 · Cited by 28
“and survival outcome in advanced RRMM patients [67,68].”
BackgroundSelf-citationUpdate on primary plasma cell leukemia
Jung, S., & Lee, J. (2022) · Blood Research · doi:10.5045/br.2022.2022033 · Cited by 26
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
Seipel, K., Porret, N. A., Wiedemann, G., Jeker, B., Bacher, U., & Pabst, T. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44040098 · Cited by 24
“A similar duration was described in the cellular kinetic analysis of the phase II trial where CAR-T cells were present in 59% of patients at 6 months and in 36% at 12 months after infusion [14].”
BackgroundMethodResultInfluentialYamamoto, C., Minakata, D., Koyama, S., Sekiguchi, K., Fukui, Y., Murahashi, R., Nakashima, H., Matsuoka, S., Ikeda, T., Kawaguchi, S., et al. (2022) · Blood · doi:10.1182/blood.2021015220 · Cited by 24
van Amerongen, R. A., Hagedoorn, R. S., Remst, D. F. G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004409 · Cited by 26
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
Li, H., Zhao, L., Sun, Z., Yao, Y., Li, L., Wang, J., Hua, T., Ji, S., Wang, S., Cheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019548 · Cited by 29
“Median platelet count, ×10(9)/L 115 (13-329) 81 (13-230) 153 (79-329)”
BackgroundKapinos, K. A., Hu, E., Trivedi, J. S., Geethakumari, P. R., & Kansagra, A. J. (2023) · Cancer Control · doi:10.1177/10732748221142945 · Cited by 28
“…response, or partial response; (2) minimal response (MR) which includes patients not meeting the criteria for BR and whose disease is not progressive; or (3) no response (NR), based on data from the three trials (DREAMM-2 for belamaf, 4 KarMMA for ide-cel, 6 and CAR-TITUDE for cilta-cel 8 ).”
MethodApplication of adoptive cell therapy in hepatocellular carcinoma
Wu, D., & Li, Y. (2023) · Immunology · doi:10.1111/imm.13677 · Cited by 29
Davis, J. A., McGann, M., Shockley, A., & Hashmi, H. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2081147 · Cited by 27
Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies
Schorr, C. R., Forindez, J., Espinoza-Gutarra, M. R., Mehta, R. P., Grover, N. S., & Perna, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098349 · Cited by 28
“2% and in MM from 5 to 12% [20]; it is possible that the higher rates of VTE in lymphoma patients is driven by the higher rates of ICANS in lymphoma-directed products when compared to MM-directed products [21,22], which reinforces the theory that systemic inflammation plays an important role in VTE development.”
ResultESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
Čufer, T., Kosty, M. P., & on behalf of the Curriculum Development Subgroup—ESMO/ASCO Global Curriculum Working Group (2023) · JCO Global Oncology · doi:10.1200/go.23.00277 · Cited by 26
Bindal, P., Patell, R. D., Chiasakul, T., Lauw, M. N., Ko, A., Wang, T., & Zwicker, J. I. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.021 · Cited by 26
Yoshikawa, T., Ito, Y., Wu, Z., Kasuya, H., Nakashima, T., Okamoto, S., Amaishi, Y., Zhang, H., Li, Y., Matsukawa, T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101526 · Cited by 26
“5 However, its long-term efficacy is not yet optimal, and objective clinical responses have not been observed in most cases following CAR-T cell therapy against solid tumors.”
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
Rocchi, S., Zannetti, B. A., Marconi, G., & Lanza, F. (2024) · Cells · doi:10.3390/cells13100853 · Cited by 30
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
Palacios‐Berraquero, M. L., Rodríguez-Márquez, P., Calleja-Cervantes, M. E., Berastegui, N., Zabaleta, A., Burgos, L., Alignani, D., Martín‐Úriz, P. S., Vilas‐Zornoza, A., Rodríguez-Diaz, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012522 · Cited by 27
“Previous clinical studies that led to the approval of Ide-Cel 2,8 and ciltacabtagene autoleucel 3,9 showed a high incidence of grade 3 and 4 cytopenia (neutropenia 89%, thrombocytopenia 52%, and anemia 60%), 1-3 ,9 a frequency similar to that found in our study.”
Ohta, K., Sakoda, Y., Adachi, K., Shinozaki, T., Nakajima, M., Yasuda, H., Nagano, H., & Tamada, K. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0226 · Cited by 30
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
Li, C., Zhou, K., Hu, Y., Zou, D., Chen, L., Chen, B., Liu, J., Zhang, X., Ren, H., Hu, K., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4879 · Cited by 30
Lawton, M. L., Inge, M. M., Blum, B. C., Smith-Mahoney, E. L., Bolzan, D., Lin, W., McConney, C., Porter, J., Moore, J., Youssef, A., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002943 · Cited by 25
Martínez-Gamboa, D. A., Hans, R., Moreno-Cortes, E. F., Figueroa-Aguirre, J., García-Robledo, J. E., Vargas-Cely, F. S., Booth, N. A., Castro-Martinez, D. A., Adams, R. H., & Castro, J. E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104648 · Cited by 26
Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
“Furthermore, while less favorable outcomes after T cell re-directing therapies, including bispecific antibodies and CAR-T cell therapies, are mainly associated with EMD (51–54), our results suggest that the distinct genomic and TME features of paramedullary disease (i.e. breakout lesions) need to be considered when li…”
InfluentialSelf-citationMechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Nasiri, F., Kozani, P. S., Salem, F., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03697-y · Cited by 30
Riedel, A., Phely, L., Hug, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015346 · Cited by 25
Biosafety considerations triggered by genome-editing technologies
Li, X., Gao, Y., Zhang, Z., Deng, W., Cao, W., Wei, X. C., Gao, Z., Yao, L., Wang, S., Xie, Y., et al. (2025) · Biosafety and Health · doi:10.1016/j.bsheal.2025.05.003 · Cited by 32
On the road to eliminating long‐lived plasma cells—“are we there yet?”
Markmann, C., & Bhoj, V. G. (2021) · Immunological Reviews · doi:10.1111/imr.13015 · Cited by 27
Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25
“The most recently approved CAR T cell product was Abecma® (Idecabtagene vicleucel) for the treatment of r/r multiple myeloma (MM) based on the results of the KarMMa trial [6,7].”
MethodImmunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?
Amsberg, G. V., Alsdorf, W. H., Karagiannis, P., Coym, A., Kaune, M., Werner, S., Graefen, M., Bokemeyer, C., Bergmann, L., & Dyshlovoy, S. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052569 · Cited by 26
A decade of CAR T cell evolution
Maus, M. V. (2022) · Nature Cancer · doi:10.1038/s43018-022-00347-4 · Cited by 24
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer
Hoyos, V., Vasileiou, S., Kuvalekar, M., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221107113 · Cited by 25
Calviño, C., Ceballos, C., Piérola, A. A., Jáuregui, P., Calleja-Cervantes, M. E., Martín‐Úriz, P. S., Rodríguez-Márquez, P., Martín-Mallo, Á., Iglesias, E., Abizanda, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270843 · Cited by 26
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 23
“CRS was reported in 84% of subjects (5% of grades 3 or higher) while neurotoxicity was observed in 16% (3% grade 3; 0% grade 4 or higher) [167].”
BackgroundHER2+ advanced gastric cancer: Current state and opportunities (Review)
Hu, H.-H., Wang, S., Zhao, H., Chen, Z., Shi, X., & Chen, X. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5624 · Cited by 30
“T cell therapy was used to treat hematological malignan‑ cies with satisfactory outcomes (139,140).”
MethodMizuhara, K., Shimura, Y., Tsukamoto, T., Kanai, A., Kuwahara‐Ota, S., Yamaguchi, J., Muramatsu, A., Okamoto, H., Katsuragawa‐Taminishi, Y., Kawaji‐Kanayama, Y., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19049 · Cited by 24
“6 While myeloma cells develop the immune escape phenotype as the disease progresses due to the expression of programmed death-ligand 1 (PD-L1) and the dysregulation of major histocompatibility complex class (MHC) I chain-related genes, 7,8 the increase in suppressive and immune-exhausted cellular…”
BackgroundFDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges
Ong, M. Z., Kimberly, S. A., Lee, W.-H., Ling, M., Lee, M., Tan, K.-W., Foo, J. B., Yow, H.-Y., Sellappans, R., & Hamzah, S. B. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010257212231001082741 · Cited by 29
Korell, F., Entenmann, L., Romann, S. W., Giannitsis, E., Schmitt, A., Müller‐Tidow, C., Frey, N., Dreger, P., Schmitt, M. W., & Lehmann, L. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102504 · Cited by 26
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations
Gatwood, K. S., Mahmoudjafari, Z., Baer, B., Pak, S., Lee, B., Kim, H., Abernathy, K. M., Dholaria, B., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.115793 · Cited by 25
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 29
Olejarz, W., Sadowski, K. A., Szulczyk, D., & Basak, G. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147743 · Cited by 26
“This therapy resulted in significant and long-lasting responses in patients with relapsed and refractory MM who have undergone extensive prior treatments [61].”
BackgroundQi, Y., Li, H., Qi, K., Zhu, F., Cheng, H., Chen, W., Yan, Z., Li, D., Sang, W., Fei, X., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27469 · Cited by 28
Arunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 27
Advances in CAR-T therapy for central nervous system tumors
Zhou, D., Zhu, X., & Xiao, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00679-6 · Cited by 25
“CAR-T therapy has shown success in treating various refractory or recurrent hematological malignancies and is considered a potentially curative approach for certain oncological conditions [2, 3].”
BackgroundUllrich, F., Bröckelmann, P. J., Turki, A. T., Khan, A., Chiru, E.-D., Vetter, M. H. F., von Tresckow, B., Wirth, R., Córdoba, R., Ortiz‐Maldonado, V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009462 · Cited by 25
“Similarly, the outcomes observed in the KarMMA study 69 that led to the FDA/EMA approval of idecabtagene vicleleucel (ide-cel) in patients with RR MM observed that both the response rate (ORR and complete response rate, CRR) and the quality of response (duration of response, DOR, and PFS) of the…”
The current socioeconomic and regulatory landscape of immune effector cell therapies
Sainatham, C., Yadav, D., Babu, A. D., Tallapalli, J. R., Kanagala, S. G., Filippov, E., Murillo-Chavez, F., Ahmed, N., & Lutfi, F. U. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1462307 · Cited by 30
Zhang, C., & Liu, H. (2025) · Journal of Immunology Research · doi:10.1155/jimr/5845167 · Cited by 27
“In CAR-T therapy applied to multiple myeloma (MM), 4 % – 33 % of patients experience relapse after receiving BCMA CAR-T therapy, potentially due to this mechanism [19, 20].”
Allogeneic CART progress: platforms, current progress and limitations
Shokati, A., Sanjari-Pour, M., Rahnama, M. A., Hoseinzadeh, S., Vaezi, M., & Ahmadvand, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557157 · Cited by 29
van de Donk, N. V., Moreau, P., San-Miguel, J., Mateos, M.-V., Dimopoulos, M., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 26
“In the KarMMa studies, ide-cel was not infused in 8·6% (KarMMa) and 9·6% of patients (KarMMa-3) who underwent leukapheresis, 3,10 and for the CARTITUDE studies, cilta-cel was not infused in 14·2% (CARTITUDE-1) and 5·8% (CARTITUDE-4) of patients who underwent leukapheresis, 4,8 which was primarily…”
InfluentialSelf-citation
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
